To validate the hypothesis that disrupting CtBP2’s function may inhibit the abnormal growth of cancer cells, we utilized the TCGA via cBioportal to explore the potential correlation of CtBP1/2 genetic alterations with patient’s overall survival time in serous ovarian cancer patients. This evidence concerns the gene CTBP2 and ovarian serous adenocarcinoma.